Partnership between Camgenium and Cardiac Tech for boosting post-surgery care with pace-protect technology
Camgenium and Cardiac Tech Partner to Develop Revolutionary Medical Device
Camgenium, a leading medical software engineering company, is partnering with MedTech innovator Cardiac Tech to develop a groundbreaking new medical device product named Pace-Protect. This device is set to be the first of its kind to use a Soft Silicon mesh network in a clinical environment.
Pace-Protect is a safety device designed to monitor all aspects of temporary pacing and report acute changes immediately to clinicians via a cloud-based platform and app. The device addresses the unmet need for safer temporary pacemakers, as research indicates that roughly 1,500 serious adverse events (SAEs) are reported each year following open-heart surgery in the US alone, attributable to the management of temporary pacemakers.
Camgenium worked closely with Cardiac Tech to develop a user interface and user workflow that is optimized for clinical use in the hospital and meets regulated and NHS standards for user interfaces within the highly demanding class II medical device environment. The Pace-Protect prototype has been developed to ISO 13485 and IEC 62304 Class IIa standards.
Soft Silicon, a highly sophisticated mesh architecture for communications using BLE and Wi-Fi, cellular, NFC and LORA, has been integrated into the Pace-Protect prototype by Camgenium. This technology ensures world-class data security for patient confidentiality and high resilience, ensuring individual Pace-Protects never loses contact with the cloud.
While there are no public updates specifically on the Pace-Protect medical device or the partnership between Camgenium and Cardiac Tech as of August 2025, the evolving regulatory environment and technological trends suggest that if Pace-Protect incorporates AI/ML or addresses unmet clinical needs in open-heart surgery follow-up, it could benefit from expedited approval pathways and improved risk management frameworks. Its potential impact on patient outcomes would depend on clinical validation and regulatory approvals aligned with these evolving frameworks.
For detailed, up-to-date information on Pace-Protect, monitoring company press releases from Camgenium and Cardiac Tech or specialized medical device regulatory news sources would be advisable.
- The collaboration between Camgenium and Cardiac Tech, in developing the Pace-Protect device, represents a fusion of science and technology, aiming to revolutionize medical-conditions management, specifically cardiovascular health, within the realm of health-and-wellness.
- The Pace-Protect device, designed for clinical trials, promises to address the critical issue of safer temporary pacemakers, with its cloud-based platform and advanced Soft Silicon mesh architecture offering world-class data security.
- As the Pace-Protect medical device and its partnership with Camgenium and Cardiac Tech navigate the regulatory environment, embracing AI/ML or addressing unmet clinical needs in open-heart surgery follow-up could expedite its approval and enhance risk management, potentially improving health outcomes substantially.
